Human respiratory syncytial virus primary prevention: Difference between revisions
Esther Lee (talk | contribs) No edit summary |
No edit summary |
||
| Line 4: | Line 4: | ||
==Overview== | ==Overview== | ||
As the virus is ubiquitous in all parts of the world, avoidance of infection is not possible. | |||
==Primary Prevention== | ==Primary Prevention== | ||
Epidemiologically, a vaccine would be the best answer. Unfortunately, vaccine development has been fraught with spectacular failure and with difficult obstacles. Researchers are working on a live, attenuated vaccine, but at present no vaccine exists. However, [[Palivizumab]] (brand name [[Synagis]]), a moderately effective [[prophylaxis|prophylactic]] drug is available for infants at high risk. Palivizumab is a [[monoclonal antibody]] directed against RSV [[protein]]s. It is given by monthly injections, which are begun just prior to the RSV season and are usually continued for five months. RSV prophylaxis is indicated for infants that are premature or have either cardiac or lung disease. | |||
==References== | ==References== | ||
| Line 14: | Line 15: | ||
[[Category:Viral diseases]] | [[Category:Viral diseases]] | ||
[[Category:Mononegavirales]] | [[Category:Mononegavirales]] | ||
{{WH}} | |||
{{WS}} | |||
Revision as of 18:20, 10 December 2012
|
Human respiratory syncytial virus Microchapters |
|
Differentiating Human Respiratory Syncytial Virus from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Human respiratory syncytial virus primary prevention On the Web |
|
American Roentgen Ray Society Images of Human respiratory syncytial virus primary prevention |
|
Human respiratory syncytial virus primary prevention in the news |
|
Blogs on Human respiratory syncytial virus primary prevention |
|
Directions to Hospitals Treating Human respiratory syncytial virus |
|
Risk calculators and risk factors for Human respiratory syncytial virus primary prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
As the virus is ubiquitous in all parts of the world, avoidance of infection is not possible.
Primary Prevention
Epidemiologically, a vaccine would be the best answer. Unfortunately, vaccine development has been fraught with spectacular failure and with difficult obstacles. Researchers are working on a live, attenuated vaccine, but at present no vaccine exists. However, Palivizumab (brand name Synagis), a moderately effective prophylactic drug is available for infants at high risk. Palivizumab is a monoclonal antibody directed against RSV proteins. It is given by monthly injections, which are begun just prior to the RSV season and are usually continued for five months. RSV prophylaxis is indicated for infants that are premature or have either cardiac or lung disease.